Answers are grounded in this paper and cite their sources.
Type 1 and type 2 diabetes both result from inadequate production of insulin by the -cells of the pancreatic islet. Accordingly, strategies that lead to increased pancreatic -cell mass, as well as retained or enhanced function of islets, would be desirable for the treatment of diabetes. Although pancreatic -cells have long been viewed as terminally differentiated and irreversibly arrested, evidence now indicates that -cells can and do replicate, that this replication can be enhanced by a variety of maneuvers, and that -cell replication plays a quantitatively significant role in maintaining pancreatic -cell mass and function. Because -cells have been viewed as being unable to pro-liferate, the science of -cell replication is undeveloped. In the past several years, however, this has begun to change at a rapid pace, and many laboratories are now focused on elucidating the molecular details of the control of cell cycle in the -cell. In this review, we review the molecular details of cell cycle control as they relate to the pancreatic -cell. Our hope is that this review can serve as a common basis and also a roadmap for those interested in developing novel strategies for enhancing -cell replication and improving insulin production in animal models as well as in human pancreatic -cells. (Endocrine Reviews 27: 356 -370, 2006) I. Introduction II. Basic Cell Cycle Machinery in the -Cell A. E2F proteins B. pRb and the "pocket proteins" C. p53 and MDM2 D. Large T-antigen E. cdk-4 and cdk-6 F. The D-cyclins G. cdk-2 and cyclins A and E H. The INK family I. The CIP/KIP/WAF family J. Menin III. Developing Models of Cell Cycle Control in the -Cell IV. Are We Looking for
No takes yet. Share an insight, caveat, or question.
Cózar‐Castellano et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: